- Molecular NameAmprenavir
- SynonymAMP; AMV; APV; VX-478
- Weight505.636
- Drugbank_IDDB00701
- ACS_NO161814-49-9
- Show 3D model
- LogP (experiment)2.064
- LogP (predicted, AB/LogP v2.0)2.68
- pka1.76; 11.54
- LogD (pH=7, predicted)2.68
- Solubility (experiment)0.04 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-5.55
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors4
- No.of HBond Acceptors9
- No.of Rotatable Bonds12
- TPSA139.57
- StatusFDA approved
- AdministrationN/A
- PharmacologyA protease inhibitor used to treat HIV infection.
- Absorption_valueN/A
- Absorption (description)Amprenavir is rapidly absorbed
- Caco_2N/A
- Bioavailability70.0
- Protein binding90.0
- Volume of distribution (VD)430 L
- Blood/Plasma Partitioning ratio (D_blood)Partitioning into erythrocytes is low.
- MetabollsmMetabolised in the liver to two major metabolites by oxidation, and minor metabolites which are glucuronide conjugates of these oxidised metabolites. In total there are 24 detected metabolites.
- Half life8 h
- Excretion<2% of the drug is recovered unchanged with the majority as metabolites in urine (14%) and faeces (75%).
- Urinary ExcretionN/A
- Clerance946 mL/min (healthy volunteers); 564 mL/min (patients with moderate cirrhosis); 295 mL/min (severe cirrhosis).
- ToxicityIn clinical studies, adverse events leading to amprenavir discontinuation occurred primarily during the first 12 weeks of therapy, and were mostly due to gastrointestinal events (nausea, vomiting, diarrhea, and abdominal pain/discomfort), which were mild to moderate in severity. Adverse events reported in >5% of adult patients also include rash, paresthesia, depressive and mood disorders.
- LD50 (rat)N/A
- LD50 (mouse)N/A